Table 1.
Classification of bladder tumors
| Characteristics | TCGA | MDA | UNC | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Luminal-papillary | Luminal-infiltrated | Luminal | Basal-squamous | Neuronal | Luminal | p53-like | Basal | Luminal | Basal | ||
| Luminal characteristics | High expression of FGFR3 | ✓✓ | ✓✓ | ✓✓ | ✓✓ | ✓✓ | |||||
| Low molecular weight keratins (KRT20) | ✓✓ | ✓✓ | ✓✓ | ✓✓ | ✓✓ | ✓✓ | |||||
| High urothelial differentiation (FOXA1, GATA3, PPARG) | ✓✓ | ✓✓ | ✓✓ | ✓✓ | ✓✓ | ✓✓ | |||||
| High uroplakins (UPK2, UPK1A) | ✓✓ | ✓✓ | ✓✓ | ✓✓ | |||||||
| High immune infiltrates | ✓✓ | ✓✓ | ✓✓ | ||||||||
| High expression of immune markers (PD1, PDL1) | ✓✓ | ✓✓ | ✓✓ | ||||||||
| Papillary morphology | ✓✓ | ||||||||||
| Basal characteristics | High molecular weight keratins (KRT5, KRT6, KRT14) | ✓✓ | ✓✓ | ✓✓ | ✓✓ | ||||||
| More stem-like phenotype | ✓✓ | ✓✓ | ✓✓ | ✓✓ | |||||||
| Upregulated EMT markers | ✓✓ | ✓✓ | ✓✓ | ✓✓ | ✓✓ | ✓✓ | |||||
| RB1 pathway alteration | ✓✓ | ✓✓ | ✓✓ | ✓✓ | |||||||
| p53 mutations | ✓✓ | ✓✓ | ✓✓ | ||||||||
| p63 activation | ✓✓ | ✓✓ | |||||||||
| High squamous differentiation markers | ✓✓ | ✓✓ | ✓✓ | ||||||||
| High neuronal differentiation | ✓✓ | ||||||||||
| Prognosis | Good | Intermediate | Intermediate | Poor | Poor | Good | Intermediate | Poor | Good | Poor | |